Hepatic Safety of Statin Use in Neurology Inpatients

Shanghai Yueyang Integrated Medicine Hospital2,000 enrolled

Overview

This research employs a cross-sectional study and a retrospective cohort study to analyze the liver safety of statin use among inpatients in the neurology department in China from different perspectives. The aim is to supplement evidence-based medicine and provide guidance for the clinical use of statins.

Study Type

OBSERVATIONAL

Enrollment

2,000

Conditions

Statin Adverse Reaction

Interventions

stainOTHER

This research was conducted in two phases. Initially, a cross-sectional study was performed to assess the correlation between statin usage prior to hospital admission and the initial state of liver enzymes among patients. Subsequently, a retrospective cohort study was undertaken, wherein patients who had not been on statins prior to admission were categorized into two groups based on their statin usage post-admission.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients hospitalized in the Department of Neurology of Yueyang Hospital from June 2020 to February 2023. 2. Age ≥18 and ≤85 years old, both sexes. 3. Meet the diagnostic criteria of cerebrovascular disease (L1-8B0), headache disease (L1-8A8) and dizziness and vertigo (MB48) in ICD-11. Exclusion Criteria: 1. Incomplete medical history. 2. 1 days ≤ patients with \< 7 days of prior statin use. 3. Patients with malignant tumors (ICD-11 code L1-2A0, L1-2A2, L1-2B5, L1-2E6 diseases) and hematological diseases (ICD-11 code L1-3A0, L1-3B1, L1-3B8 diseases).

Locations (1)

Shanghai Yueyang Integrated Medicine Hospital

Shanghai, Shanghai Municipality, China

RECRUITING

Outcomes

Primary Outcomes

Aspartate aminotransferase(AST)

The specific value of AST, whether the AST was more than 1 times the upper limit of normal (\>1×ULN), and whether it was more than 3×ULN.

Time frame: 4weeks after admission.

Alanine aminotransferase(ALT)

The specific value of ALT, whether the ALT was more than 1 times the upper limit of normal (\>1×ULN), and whether it was more than 3×ULN.

Time frame: 4 weeks taken after admission.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.